GSK and J&J Lead in Addressing Antimicrobial Resistance, Report Says

Drug Industry Daily
A A
Drugmakers must do more to ensure access to treatments for antimicrobial-resistant superbugs, but GlaxoSmithKline and Johnson & Johnson are doing more than other organizations on 16 metrics of progress, according to the Access to Medicines Foundation, a Netherlands-based non-profit.

To View This Article:

Login

Subscribe To Drug Industry Daily